Inlyta Approval Expands Pfizer Kidney Cancer Options, But With Unique Safety Profile

By Shirley Haley / Email the Author / “The Pink Sheet” DAILY Jan. 27, 2012
Word Count: 688 / Article # 14120127004

Executive Summary

Second-generation VEGF inhibitor Inlyta (axitinib) gained approval based as much on its complementary safety profile as its superiority in a head-to-head comparison with Bayer/Onyx’s Nexavar .

Purchase this Article

$35.00 Buy Now

For $35.00, purchase this 688-word article and receive immediate online access. 100% Satisfaction Guarantee.

View a complete sample article »

Already a Subscriber?

Log in for complete access.

Questions?

Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.

Log In

Email Address

Password

Remember Me

Forgot your password?

Don’t Have an Account?

If your employer has a site license, create your account to begin using it. Simply click ‘Create An Account’ button below to register now.

Otherwise, please explore our free content subscriptions.

Create an account

Enter the email address associated with your account and a temporary password will be sent to you.

Email Address

Need help? Contact us at (800) 332-2181, +1 (908) 547-2159, or custcare@elsevier.com

Email Article

* Required field

* To:

For multiple recipients, separate email addresses with a semi-colon.

* Your Name:

* Your Email:

Subject: Inlyta Approval Expands Pfizer Kidney Cancer Options, But With Unique Safety Profile

* Add a personalized message to your email:

Please Note: Only individuals with subscriptions to “The Pink Sheet” DAILY will be able to access the full article. All other readers will be directed to the abstract and may purchase the article.

or Cancel

Inlyta Approval Expands Pfizer Kidney Cancer Options, But With Unique Safety Profile

Executive Summary

Purchase this Article

Already a Subscriber?

Questions?

Related Articles: 10

Elsevier Business Intelligence Publications

Offers & Events

Topics Covered in this Article

Email Article